A Study Explore JS001+IMP4297 in Patients With Advanced Cancer
Status:
Not yet recruiting
Trial end date:
2024-06-06
Target enrollment:
Participant gender:
Summary
This is a Phase I/Ib open-label, multicenter study to evaluate the safety, tolerability,
pharmacokinetics (PK), immunogenicity and antitumor activity of toripalimab in combination
with senaparib in patients with advanced solid tumors. The study consists of 2 parts, the
Phase I part of the study will be a dose-escalation evaluation to determine the RP2D of
senaparib to be administered in combination with the fixed dose of toripalimab, and the Phase
Ib portion will further evaluate the RP2D and evaluate the efficacy of combination in
specific types of advanced solid tumors.